Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

March 31, 2016

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Rituximab, CMC544, Gemcitabine and Oxaliplatine

"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."

Trial Locations (11)

8000

AZ Sint Jan, Bruges

9000

University Hospital Gent, Ghent

21000

CHU de Dijon, Dijon

35003

CHU Pontchaillou, Rennes

44093

CHU Hôtel Dieu, Nantes

54511

CHU Brabois, Vandœuvre-lès-Nancy

59037

CHRU de Lille, Lille

69495

CHU Lyon - Sud, Lyon

76038

Centre Henri Becquerel, Rouen

94010

Hôpital Henri Mondor, Créteil

Unknown

CHU Mont-Godinne, Yvoir

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

The Lymphoma Academic Research Organisation

OTHER

NCT01562990 - Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | Biotech Hunter | Biotech Hunter